Article Type
Original Study
Abstract
Diabetes mellitus (DM) is a clear risk factor for stroke. Furthermore, diabetes has been shown to be a strong determinant for the presence of multiple lacunar infarcts in stroke patients. There has been a recent appreciation that peroxisome prolifera-tor-activated receptors (PPARs) and their ligands may play an important role in the brain. An increasing number of studies have reported on the effects of PPAR agonists in animal models of neurological damage and disease, including the excitatory damage that occurs in stroke. The PPARy agonist, rosiglitazone, a synthetic li-gand of the thiazolidinedione class was currently used as an antidiabetic agent because of its insulin- sensitizing effect. So, the purpose of this study was to determine whether rosigiitazone may be neuroprotective in a model of permanent focal cerer-bral ischemia in diabetic rats. Methods: This study was carried on 96 albino rats. Rats were divided into 8 equal groups: Group (1): Control group, Group (2): Diabetic control group, Group (3): Non-treated is-chemic group, Group (4): Diabetic and non-treated sham operated group, Group (5): Diabetic and non-treated permanent left middle cerebral artery occlusion group, Group < /p> (6): Treated ischemic group, Group < /p> (7): Diabetic and treated sham operated group, Group (8): Diabetic and treated permanent middle cerebral artery occlusion group.
Recommended Citation
Shalaby, A and Boshra, V
(2008)
"EVALUATION OF THE ANTI-ISCHEMIC EFFECT OF THE PPARy AGONIST, (ROSIGLITAZONE) IN PERMANENT FOCAL CEREBRAL ISCHEMIA IN DIABETIC RATS.,"
Mansoura Medical Journal: Vol. 37
:
Iss.
1
, Article 3.
Available at:
https://doi.org/10.21608/mjmu.2008.128912
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.